ST步森(002569.SZ):5%以上股東上海睿鷙所持268萬股將被司法拍賣
格隆匯11月9日丨ST步森(002569.SZ)公佈,公司於近日收到上海一中院委託上海國泰拍賣行有限責任公司發來的就長城資本管理有限公司與公司持股5%以上股東上海睿鷙資產管理合夥企業(有限合夥)(以下簡稱“上海睿鷙”)等關於公證執行證書一案下發的《網絡司法拍賣事項通知書》,上海一中院已在“淘寶網”發佈了相關股權拍賣公告,將於2020年12月12日8時至2020年12月13日8時公開拍賣上海睿鷙持有的步森股份268萬股股票(約佔公司總股本的1.86%)。
目前拍賣事項尚在公示階段,後續將涉及競拍、繳款、法院裁定、股權變更過户等環節,如本次拍賣完成,公司控股股東不會發生變化
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.